Article
Potential treatment: Miravant regains rights to wet AMD therapy
Santa Barbara, CA-Miravant Medical Technologies plans to seek new applications for its primary drug candidate, a potential therapy for wet age-related macular degeneration (AMD)
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
